Share

cover art for Presenting STAT’s First Opinion: How Two Abortion Providers Grapple with Their Post-Roe Reality

Tradeoffs

Presenting STAT’s First Opinion: How Two Abortion Providers Grapple with Their Post-Roe Reality

Season 1, Ep. 250

From where medical students are choosing to train to how doctors are caring for women in reproductive health crises, the Supreme Court's decision to overturn Roe has had major ripple effects on the field of medicine. In this conversation from our friends at STAT's First Opinion podcast, host Torie Bosch talks with two abortion providers about what it's like to practice medicine in post-Roe America.


Learn more and read a full transcript on our website.


Support this type of journalism today, with a gift, which for a limited time will be matched!

More episodes

View all episodes

  • 294. How Did Picking a Medicare Plan Get So Hard?

    24:36||Season 1, Ep. 294
    It’s Medicare open enrollment season, and in this episode first aired in 2021, we explain why shopping for a new plan is often tougher than it seems.Guests:Lilyan Grossman, Medicare beneficiaryTricia Neuman, ScD, Senior Vice President and Executive Director of the Program on Medicare Policy, Kaiser Family FoundationAmal Trivedi, MD, Professor of Medicine and Health Services, Policy, and Practice, Brown UniversityLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 293. What the Election Could Mean for Obamacare

    17:19||Season 1, Ep. 293
    One of the nation’s leading experts on the Affordable Care Act breaks down its track record and weighs in on the stakes the historic health care law faces in the lead-up to the election.Guest:Larry Levitt, Executive Vice President for Health Policy, KFFLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 292. 3 Health Care Decisions Awaiting the Next President

    26:27||Season 1, Ep. 292
    The next U.S. president will have to make consequential choices about the Affordable Care Act, prescription drug prices and abortion. We compare the positions of candidates Kamala Harris and Donald Trump on these major health policy issues. (NOTE: This episode has been updated to clarify the number of people who would lose health coverage if Affordable Care Act enhanced subsidies expired.)Guests:Michael Cannon, Director of Health Policy Studies, Cato InstituteEderlina Co, JD, Associate Professor of Law, University of the PacificCynthia Cox, Vice President and Director of Program on the ACA, KFFStacie Dusetzina, PhD, Professor of Health Policy, Vanderbilt University Medical CenterBenedic Ippolito, PhD, Senior Fellow, American Enterprise InstituteRyan Levi, Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 291. How New York Times Columnist Paula Span Navigates ‘The New Old Age’

    23:45||Season 1, Ep. 291
    Journalist Paula Span, who writes The New Old Age column for the New York Times, shares what she’s learned about how to age well.Guest:Paula Span, reporter and The New Old Age columnist for the New York TimesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 290. Why Employers Are Turning to Primary Care as Health Care Costs Soar

    20:48||Season 1, Ep. 290
    U.S. companies spend more than $1 trillion annually on health care for their employees. To get this budget-busting figure under control, some companies are experimenting with cutting out insurers, and investing in primary care clinics at the office.  Guests:Amy Cooper, NP, Vera Whole HealthBob Galvin, MD, former Chief Medical Officer, General Electric and Board Chairman, Catalyst for Payment ReformDan Mendelson, CEO, Morgan HealthAnn O’Malley, MD, MPH, Senior Fellow, MathematicaMatt Ohrt, Co-founder, Self Fund HealthLee Sagraves, Employee, JPMorganChaseGwen SagravesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 289. The Best Way to Fight Meth Addiction? Gift Cards

    27:19||Season 1, Ep. 289
    For decades, the most effective treatment for addiction to methamphetamine or cocaine has been mired in stigma and mostly limited to small research studies. But with deaths involving meth and cocaine on the rise, policymakers across the country are turning to gift cards to fight drug use.This story has been updated to clarify the research on long-term effects of contingency management and the eligibility requirements to deliver contingency management through CalAIM.Credits:Stephen Higgins, PhD, Professor of Psychology and Psychiatry, University of VermontRichard Rawson, PhD, Professor Emeritus, UCLA Department of PsychologyAndrew Dertien, Contingency Management Coordinator, HealthRIGHT 360Bernard GrovesAyesha Appa, MD, Assistant Professor of Medicine, UCSF and San Francisco General HospitalTyler Sadwith, Medicaid Director, California Department of Health Care ServicesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 288. Race to the Bottom: Where's the Cavalry?

    27:38||Season 1, Ep. 288
    Many potent new medicines pose a host of challenges for drug companies trying to copy and sell similar versions on the cheap. Can those companies find a sustainable path forward, or will patients get left stuck paying exorbitant prices?Guests:Christine Baeder, MBA, President, Apotex USAAlfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical Industry AssociationJeremy Greene, MD, PhD, Professor of Medicine and the History of Medicine, Johns Hopkins UniversityCandy Meyer, PatientBhaven Sampat, PhD, Professor, Arizona State University School for the Future of Innovation in SocietyMarta Wosińska, PhD, Senior Fellow, Brookings InstitutionLeslie Walker, Senior Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 287. Race to the Bottom: Hard Bargain

    28:12||Season 1, Ep. 287
    America pays less, on average, than any other major country for our generic drugs. But selling essential drugs at such low prices comes with hidden costs — from quality problems to frequent shortages.This is the second episode of Race to the Bottom, a three-part series by Tradeoffs on the problems plaguing the generic drugs we all rely on — and how we could fix them.Guests:Christine Baeder, MBA, President, Apotex USALaura Bray, MBA, Founder, Angels for ChangeCraig Burton, Senior Vice President of Policy and Strategic Alliances, Association for Accessible MedicinesIilun Murphy, MD, Director of the Office of Generic Drugs, FDALeslie Walker, Senior Reporter/Producer, TradeoffsMarta Wosińska, PhD, Senior Fellow, Brookings InstitutionLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.
  • 286. Race to the Bottom: Boom Times

    27:37||Season 1, Ep. 286
    Generic drugs are, in many ways, the unsung hero of America’s health care system, bringing powerful medical innovations within the reach of millions more people. These cheaper copies of brand-name drugs — from pills that stop heart attacks to antibiotics that cure life-threatening infections — save America hundreds of billions of dollars a year. But will affordable, high-quality generic drugs continue to be there when we need them?Some players are abandoning this business while others slash costs by cutting dangerous corners. Shortages of older generic drugs have become the norm, sending doctors scrambling. At the same time, crucial new medicines are proving tougher to copy on the cheap, saddling patients with brand-name prices.Over the course of “Race to the Bottom,” our new three-part podcast series, we’ll explore why this industry that’s so essential to our health is in trouble — and what could change that.In part one, we examine the history of this industry. Forty years ago this month, President Ronald Reagan signed groundbreaking, bipartisan legislation that gave birth to a new drug market. Lawmakers made choices back then that help explain the wild success and also the troubles we see today with generic medicines.Guests:Christine Baeder, MBA, President, Apotex USAAlfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical AssociationLeslie Walker, Senior Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.